Ticker > Company >

Lasa Supergenerics share price

Lasa Supergenerics Ltd.

NSE: LASA BSE: 540702 SECTOR: Pharmaceuticals & Drugs  37.82 K   54   4

8.88
+0.08 (0.91%)
NSE: 05 Sep 4:00 PM

Price Summary

Today's High

₹ 8.9

Today's Low

₹ 8.41

52 Week High

₹ 31.4

52 Week Low

₹ 8.16

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

44.49 Cr.

Enterprise Value

65.07 Cr.

No. of Shares

5.01 Cr.

P/E

0

P/B

0.71

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  12.49

CASH

1.5 Cr.

DEBT

22.08 Cr.

Promoter Holding

53.65 %

EPS (TTM)

₹  -6.62

Sales Growth

-19.47%

ROE

-20.22 %

ROCE

-13.23%

Profit Growth

43.73 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-19.47%
3 Year-19.82%
5 Year-9.26%

Profit Growth

1 Year43.73%
3 Year-198.44%
5 Year-27.98%

ROE%

1 Year-20.22%
3 Year-17.18%
5 Year-6.69%

ROCE %

1 Year-13.23%
3 Year-13.53%
5 Year-3.33%

Debt/Equity

0.2284

Price to Cash Flow

20.8

Interest Cover Ratio

-8.5966

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 53.65 20.66
Mar 2025 53.65 20.66
Dec 2024 53.65 20.66
Sep 2024 53.65 20.66
Jun 2024 53.65 20.66
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 11.2655 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 32.1483596389387.

 Limitations

  • The company has shown a poor profit growth of -198.443553738875% for the Past 3 years.
  • The company has shown a poor revenue growth of -19.8158013930484% for the Past 3 years.
  • Company has a poor ROE of -17.1842402531272% over the past 3 years.
  • Company has a poor ROCE of -13.5257916170315% over the past 3 years
  • Company has low Interest coverage ratio of -8.5966.
  • Promoter pledging is high as 20.66%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 30.84 39.4 33.08 39.14 20.01
Total Expenditure 29.04 38.6 32.29 35.73 20.51
Operating Profit 1.8 0.79 0.79 3.41 -0.5
Other Income 0.01 1.95 0.14 2.39 0.13
Interest 0.87 1.24 0.47 0.11 0.03
Depreciation 2.79 2.81 2.8 3.9 1.57
Exceptional Items 0 0 8.25 -23.91 -20.58
Profit Before Tax -1.86 -1.31 5.91 -22.12 -22.54
Tax 0.87 1.92 0.42 -7.83 -1.42
Profit After Tax -2.73 -3.23 5.49 -14.29 -21.12
Adjusted EPS (Rs) -0.55 -0.64 1.1 -2.85 -4.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 167.26 202.38 137.13 129.57 104.34
Total Expenditure 137.29 155.17 121.11 136.17 102.11
Operating Profit 29.97 47.21 16.02 -6.6 2.22
Other Income 0.23 0.18 0.28 1.84 0.1
Interest 8.12 2.06 0.06 4.19 1.99
Depreciation 17.34 15.82 14.51 13.42 10.67
Exceptional Items 0 0 -7.86 -19.9 -8.77
Profit Before Tax 4.74 29.49 -6.14 -42.27 -19.11
Tax 1.11 6.71 -0.81 -3.64 2.62
Net Profit 3.63 22.78 -5.33 -38.62 -21.73
Adjusted EPS (Rs.) 0.89 5.6 -1.06 -7.71 -4.34

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 40.67 40.67 50.1 50.1 50.1
Total Reserves 100.79 118.24 107.78 68.18 46.58
Borrowings 14.14 0 0 0 0
Other N/C liabilities -2.71 8.41 6.54 2.84 5.32
Current liabilities 75.92 40.54 44.75 42.73 48.87
Total Liabilities 228.81 207.86 209.17 163.85 150.87
Assets
Net Block 152.19 142.95 137.28 118.96 109.76
Capital WIP 0 0 4.58 4.64 2.51
Intangible WIP 0 0 0 0 0
Investments 0 0 0.38 0.39 0
Loans & Advances 0.75 0.59 0.63 0.59 0.71
Other N/C Assets 0 0 0 0.05 0
Current Assets 75.87 64.32 66.3 39.22 37.89
Total Assets 228.81 207.86 209.17 163.85 150.87
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 4.74 29.49 1.72 -22.37 -19.11
Adjustment 25.27 17.75 6.5 -4.07 8.42
Changes in Assets & Liabilities -16.01 -5.93 3.59 9.18 12.83
Tax Paid -0.37 0 -2.59 -0.04 0
Operating Cash Flow 13.62 41.31 9.21 -17.3 2.14
Investing Cash Flow -1.63 -3.6 -2.91 11.19 -0.4
Financing Cash Flow -9.85 -36.44 -0.04 -4.16 -1.93
Net Cash Flow 2.15 1.27 6.26 -10.27 -0.19

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 53.65 53.65 53.65 53.65 53.65
omkar pravin herlekar - - - 53.65 53.65
omkar pravin herleker 53.65 53.65 53.65 - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Jun 2025%
investors 46.35 46.35 46.35 46.35 46.35
mahendra girdharilal wadh... - - - - 1.00
bnp enterprises 8.48 8.48 8.48 8.48 -
anil vishanji dedhia 1.30 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY20
Concall Q3FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY20
Presentation Q2FY21

Company News

Lasa Supergenerics - Quaterly Results 13 Aug, 5:57 PM Lasa Supergenerics - Quaterly Results 13 Aug, 5:57 PM Lasa Supergenerics informs about financial results 28 May, 5:19 PM Lasa Supergenerics - Quaterly Results 28 May, 5:07 PM Lasa Supergenerics expands manufacturing capacity of API Albendazole 25 Apr, 12:30 PM Lasa Supergenerics informs about outcome of EGM 22 Feb, 12:20 PM Lasa Supergenerics informs about board meeting 5 Feb, 4:00 PM Lasa Supergenerics informs about closure of trading window 30 Sep, 4:58 PM Lasa Supergenerics informs about disclosure 13 Sep, 5:24 PM Lasa Supergenerics gets patent from Controller of Patents 13 Sep, 4:52 PM Lasa Supergenerics - Quaterly Results 14 Aug, 4:56 PM Lasa Supergenerics - Quaterly Results 13 Feb, 6:26 PM Lasa Supergenerics - Quaterly Results 9 Jun, 4:46 PM Lasa Supergenerics - Quaterly Results 9 Jun, 4:46 PM Lasa Supergenerics - Quaterly Results 9 Jun, 4:46 PM Lasa Supergenerics informs about postponement of board meeting 7 Jun, 4:58 PM Lasa Supergenerics informs about disclosure of related party transactions 28 Nov, 4:43 PM Lasa Supergenerics informs about outcome of board meeting 26 Aug, 4:45 PM Lasa Supergenerics - Quaterly Results 8 Aug, 3:13 PM Lasa Supergenerics - Quaterly Results 8 Aug, 3:13 PM Lasa Supergenerics secures new order of Rs 50 crore from just 5 customers 27 Apr, 10:30 AM Lasa Supergenerics reports over 3-fold jump in Q4 net profit 12 Apr, 12:07 PM Lasa Supergenerics informs about press release 11 Apr, 4:55 PM Lasa Supergenerics - Quaterly Results 11 Apr, 1:17 PM Lasa Supergenerics - Quaterly Results 11 Apr, 1:17 PM Lasa Supergenerics - Quaterly Results 11 Apr, 1:17 PM Lasa Supergenerics informs about board meeting 21 Mar, 9:45 AM Lasa Supergenerics files another suit for permanent injunction against one of its competitors 10 Mar, 9:59 AM Lasa Supergenerics - Quaterly Results 7 Feb, 3:41 PM Lasa Supergenerics - Quaterly Results 7 Feb, 3:41 PM Lasa Supergenerics - Quaterly Results 7 Feb, 3:41 PM Lasa Supergenerics informs about disclosure 4 Feb, 10:02 AM Lasa Supergenerics informs about press release 16 Dec, 9:30 AM Lasa Supergenerics resumes operations in all units situated in Mahad, Chiplun 23 Aug, 2:34 PM Lasa Supergenerics reports 85% fall in Q1 net profit 18 Aug, 12:12 PM Lasa Supergenerics board approves financial results 16 Aug, 1:42 PM Lasa Supergenerics informs about board meeting 6 Aug, 2:49 PM Lasa Supergenerics informs about press release 26 Jul, 4:24 PM Lasa Supergenerics informs about press release 9 Jun, 2:47 PM Lasa Supergenerics launches new product Oxyclozanide 9 Jun, 12:15 PM Lasa Supergenerics informs about earnings call 1 Jun, 4:35 PM Lasa Supergenerics informs about outcome of board meeting 31 May, 4:18 PM Lasa Supergenerics informs about PCS certificate 26 Apr, 3:58 PM Lasa Supergenerics submits RTA certificate 18 Jan, 1:52 PM Lasa Supergenerics gets WHO Certificate of Good Manufacturing Practices for Khed unit 12 Jan, 12:40 PM Lasa Supergenerics gets environmental clearance for Benzimidazole Derivatives Capacity Expansion 4 Nov, 12:42 PM Lasa Supergenerics informs about media release 8 Jun, 10:37 AM Lasa Supergenerics gets FDA’s nod to manufacture Progesterone0 13 Apr, 9:21 AM

Lasa Supergenerics Stock Price Analysis and Quick Research Report. Is Lasa Supergenerics an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Lasa Supergenerics. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Lasa Supergenerics has a PE ratio of -1.34220072551391 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Lasa Supergenerics has ROA of -13.8093% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Lasa Supergenerics has a Current ratio of 0.7753.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Lasa Supergenerics has a ROE of -20.2181%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Lasa Supergenerics has a Debt to Equity ratio of 0.2284 which means that the company has low proportion of debt in its capital.

  • Sales growth: Lasa Supergenerics has reported revenue growth of -19.4746% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Lasa Supergenerics for the current financial year is 2.13025351032731%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Lasa Supergenerics is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Lasa Supergenerics is Rs -6.616. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Lasa Supergenerics in Ticker for free. Also, one can get the intrinsic value of Lasa Supergenerics by using Valuation Calculators, which are available with a Finology ONE subscription. 

Lasa Supergenerics FAQs

Q1. What is Lasa Supergenerics share price today?
Ans: The current share price of Lasa Supergenerics is Rs 8.88.

Q2. What is the market capitalisation of Lasa Supergenerics?
Ans: Lasa Supergenerics has a market capitalisation of Rs 44.489900232 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Lasa Supergenerics?
Ans: The PE ratio of Lasa Supergenerics is -1.34220072551391 and the P/B ratio of Lasa Supergenerics is 0.710775289352778, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Lasa Supergenerics share?
Ans: The 52-week high share price of Lasa Supergenerics is Rs 31.4, and the 52-week low share price of Lasa Supergenerics is Rs 8.16.

Q5. Does Lasa Supergenerics pay dividends?
Ans: Currently, Lasa Supergenerics does not pay dividends. Dividend yield of Lasa Supergenerics is around 0%.

Q6. What are the face value and book value of Lasa Supergenerics shares?
Ans: The face value of Lasa Supergenerics shares is Rs 10, while the book value per share of Lasa Supergenerics is around Rs 12.4934. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Lasa Supergenerics?
Ans: Lasa Supergenerics has a total debt of Rs 22.0762 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Lasa Supergenerics?
Ans: The ROE of Lasa Supergenerics is -20.2181% and ROCE of Lasa Supergenerics is -13.2306%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Lasa Supergenerics a good buy for the long term?
Ans: The Lasa Supergenerics long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Lasa Supergenerics undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Lasa Supergenerics appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Lasa Supergenerics’s financials?
Ans: You can review Lasa Supergenerics’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Lasa Supergenerics
X